|
1
|
Coget J, Borrini F, Susman S and Sabourin
JC: Colorectal carcinomas in 2013: the search for powerful
prognostic markers is still on the go! Cancer Biomark. 14:145–150.
2014.PubMed/NCBI
|
|
2
|
No authors listed. Efficacy of adjuvant
fluorouracil and folinic acid in colon cancer. International
Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT)
investigators. Lancet. 345:939–944. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
González-Vallinas M, Molina S, Vicente G,
et al: Antitumor effect of 5-fluorouracil is enhanced by rosemary
extract in both drug sensitive and resistant colon cancer cells.
Pharmacol Res. 72:61–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Etienne MC, Chazal M, Laurent-Puig P, et
al: Prognostic value of tumoral thymidylate synthase and p53 in
metastatic colorectal cancer patients receiving fluorouracil-based
chemotherapy: phenotypic and genotypic analyses. J Clin Oncol.
20:2832–2843. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Copur S, Aiba K, Drake JC, Allegra CJ and
Chu E: Thymidylate synthase gene amplification in human colon
cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol.
49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnston PG, Lenz HJ, Leichman CG, et al:
Thymidylate synthase gene and protein expression correlate and are
associated with response to 5-fluorouracil in human colorectal and
gastric tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
|
|
7
|
Yeh KH, Shun CT, Chen CL, et al: High
expression of thymidylate synthase is associated with the drug
resistance of gastric carcinoma to high dose 5-fluorouracil-based
systemic chemotherapy. Cancer. 82:1626–1631. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang LY, Liu M, Li X and Tang H:
miR-490-3p modulates cell growth and epithelial to mesenchymal
transition of hepatocellular carcinoma cells by targeting
endoplasmic reticulum-Golgi intermediate compartment protein 3
(ERGIC3). J Biol Chem. 288:4035–4047. 2013. View Article : Google Scholar :
|
|
9
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fujita Y, Kojima K, Hamada N, et al:
Effects of miR-34a on cell growth and chemoresistance in prostate
cancer PC3 cells. Biochem Biophys Res Commun. 377:114–119. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hwang JH, Voortman J, Giovannetti E, et
al: Identification of microRNA-21 as a biomarker for
chemoresistance and clinical outcome following adjuvant therapy in
resectable pancreatic cancer. PLoS One. 5:e106302010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bitarte N, Bandres E, Boni V, et al:
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and
chemoresistance of colorectal cancer stem cells. Stem Cells.
29:1661–1671. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karaayvaz M, Zhai H and Ju J: miR-129
promotes apoptosis and enhances chemosensitivity to 5-fluorouracil
in colorectal cancer. Cell Death Dis. 4:e6592013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gotanda K, Hirota T, Matsumoto N and Ieiri
I: MicroRNA-433 negatively regulates the expression of thymidylate
synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa
cells. BMC Cancer. 13:3692013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Djeu JY and Wei S: Clusterin and
chemoresistance. Adv Cancer Res. 105:77–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li JA, Chen YX, Zhao JF, Kong FR and Zhang
YD: miR-203 reverses chemoresistance in p53-mutated colon cancer
cells through downregulation of Akt2 expression. Cancer Lett.
304:52–59. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin J, Zheng G, Jia X, et al: A
Bmi1-miRNAs cross-talk modulates chemotherapy response to
5-fluorouracil in breast cancer cells. PLoS One. 8:e732682013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Viticchie G, Lena AM, Latina A, et al:
MiR-203 controls proliferation, migration and invasive potential of
prostate cancer cell lines. Cell Cycle. 10:1121–1131. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Wan G, Spizzo R, et al: miR-203
induces oxaliplatin resistance in colorectal cancer cells by
negatively regulating ATM kinase. Mol Oncol. 8:83–92. 2014.
View Article : Google Scholar
|
|
21
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian L, Li M, Ge J, et al: MiR-203 is
downregulated in laryngeal squamous cell carcinoma and can suppress
proliferation and induce apoptosis of tumours. Tumour Biol.
35:5953–5963. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lehman NL: Future potential of thymidylate
synthase inhibitors in cancer therapy. Expert Opin Investig Drugs.
11:1775–1787. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Houghton JA, Tillman DM and Harwood FG:
Ratio of 2′-deoxyadenosine-
5′-triphosphate/thymidine-5′-triphosphate influences the commitment
of human colon carcinoma cells to thymineless death. Clin Cancer
Res. 1:723–730. 1995.PubMed/NCBI
|
|
25
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
a systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lenz HJ, Hayashi K, Salonga D, et al: p53
point mutations and thymidylate synthase messenger RNA levels in
disseminated colorectal cancer: an analysis of response and
survival. Clin Cancer Res. 4:1243–1250. 1998.PubMed/NCBI
|
|
27
|
Cho YB, Chung HJ, Lee WY, et al:
Relationship between TYMS and ERCC1 mRNA expression and in vitro
chemosensitivity in colorectal cancer. Anticancer Res.
31:3843–3849. 2011.PubMed/NCBI
|
|
28
|
Galbiatti AL, Caldas HC, Maniglia JV,
Pavarino EC and Goloni-Bertollo EM: Gene expression profile of
5-fluorouracil metabolic enzymes in laryngeal cancer cell line:
predictive parameters for response to 5-fluorouracil-based
chemotherapy. Biomed Pharmacother. 68:515–519. 2014. View Article : Google Scholar : PubMed/NCBI
|
